文献速递淋巴瘤

泽布替尼单药治疗复发/难治性惰性非霍奇金淋巴瘤

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

BGB-3111-AU-003 是一项 1/2 期、开放标签、多中心、单药研究,纳入 385 例 B 细胞恶性肿瘤患者。本文报告其中 53 例复发/难治性边缘区淋巴瘤(MZL,n=20)和滤泡性淋巴瘤(FL,n=33)患者的安全性与疗效,均接受推荐 2 期剂量的泽布替尼。MZL 的 ORR 为 80%、CR 为 20%,中位随访 33.8 个月 PFS 未达到;FL 的 ORR 为 36.4%、CR 为 18.2%,中位随访 33.9 个月中位 PFS 为 10.4 个月。

要点

  • 复发/难治性 MZL 患者 ORR 80%、CR 20%,中位随访 33.8 个月 PFS 未达到。
  • 复发/难治性 FL 患者 ORR 36.4%、CR 18.2%,中位随访 33.9 个月中位 PFS 10.4 个月。
  • 泽布替尼总体耐受良好,多数不良事件≤2 级,未报告心房颤动/扑动。

核心结论

  • 本研究结果提示泽布替尼具有有利的获益-风险特征,支持其可能成为复发/难治性 MZL 和 FL 患者现有治疗的有意义补充。

研究设计与样本

  • BGB-3111-AU-003 是一项 1/2 期、开放标签、多中心、单药研究,纳入 385 例 B 细胞恶性肿瘤患者。
  • 本文报告 53 例复发/难治性 MZL(n=20)和复发/难治性 FL(n=33)患者,均在 2 期剂量扩展部分入组并接受推荐 2 期剂量的泽布替尼。

主要发现

  • MZL 患者 ORR 为 80%,CR 率为 20%,中位随访 33.8 个月,中位 PFS 未达到。
  • FL 患者 ORR 为 36.4%,CR 率为 18.2%,中位随访 33.9 个月,中位 PFS 为 10.4 个月。
  • 治疗总体耐受良好,多数不良事件≤2 级,未报告心房颤动/扑动,2 例需减量,4 例因不良事件停药。

关键数值与推荐

  • MZL 疗效由独立评审委员会评估,FL 由研究者评估,均采用 Lugano 2014 非霍奇金淋巴瘤分类标准。
  • MZL:ORR 80%,CR 20%,中位随访 33.8 个月,中位 PFS 未达到。
  • FL:ORR 36.4%,CR 18.2%,中位随访 33.9 个月,中位 PFS 10.4 个月。

临床怎么用

  • 原文结论提示泽布替尼可能成为复发/难治性 MZL 和 FL 患者现有治疗的有意义补充。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. BGB-3111-AU-003 was a phase 1/2, open-label, multicenter, single-agent study of the selective Bruton's tyrosine kinase inhibitor zanubrutinib in 385 patients with B-cell malignancies. Here, we present safety and efficacy outcomes for the 53 enrolled patients with relapsed/refractory MZL (n = 20) and relapsed/refractory FL (n = 33), all of whom were enrolled during the part 2 dose expansion, and therefore received zanubrutinib at the recommended phase 2 dose. Treatment with zanubrutinib was generally well tolerated, with most adverse events being ≤ grade 2. Atrial fibrillation/flutter was not reported. Two patients required dose reduction, and 4 patients discontinued treatment because of adverse events. Response was assessed by an independent review committee for MZL and the investigators for FL, per Lugano 2014 classification for non-Hodgkin lymphoma. In patients with MZL, the overall response rate (ORR) was 80%, and the complete response (CR) rate was 20%. With median follow-up of 33.8 months, median progression-free survival (PFS) was not reached. In patients with FL, the ORR was 36.4%, and the CR rate was 18.2%. After a median follow-up of 33.9 months, median PFS was 10.4 months. In conclusion, the results of this study suggest a favorable benefit-risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with relapsed/refractory MZL and FL. This trial was registered at www.clinicaltrials.gov as #NCT02343120.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Phillips T, Chan H, Tam CS, et al. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2022. PMID: 35390135. doi:10.1182/bloodadvances.2021006083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。